Markus Rudin studied chemistry at ETH Zürich, Switzerland, and graduated in the Physical Chemistry Laboratory working on electron-nuclear double resonance (ENDOR) of transition metal complexes. After post-doctoral stays at ETH and the Biocenter of the University of Basel, he joined Sandoz Pharma AG in Basel, Switzerland, in 1983 to establish one of the first MRI imaging labs in pharmaceutical industry world-wide. Within Sandoz, to become Novartis AG in 1996, he became head of the global Analytical and Imaging Science Unit and deputy head of the Core Technology Area, before he moved to academia in 2005 to become full professor for Molecular Imaging and Functional Pharmacology at the University of Zürich and ETH Zürich.
His research topics are the development of small animal imaging techniques, in particular MRI, fluorescence imaging as well as the combination of fluorescence molecular tomography and MRI, with application of these techniques in the field of neuroscience and oncology. Primary focus in neuroscience is the study of brain function under normal and pathological conditions and the elucidation of mechanisms underlying the hemodynamic fMRI signal. In oncology, the principal research topic is the development of imaging assays to study tumor hypoxia, hypoxia signaling and its downstream effects on angiogenesis, metabolism and tissue invasion.